Biosergen publishes interim report for first quarter 2023
Monday, August 14, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q2 2023
2023 | 2022 | 2023 | 2022 | 2022 | |
TSEK | April-June | April-June | Jan-June | Jan-June | Jan-Dec |
Profit/loss | |||||
Other income | 2.456 | 1.409 | 7.771 | 2.726 | 5.183 |
Profit/loss before depreciation (EBITDA | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
Operating profit/loss befor net financials | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
Net financials | 7 | 3 | 9 | 6 | 81 |
Netprofit/loss for the period | -8.031 | -7.960 | -13.058 | -12.975 | -34.048 |
Earnings per share (SEK) | -0,19 | -0,28 | -0,31 | -0,46 | -1,09 |
Highlights during Q2 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
Highlights after the period
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net
Certified Adviser
Erik Penser Bank
Telefon: +46 8 463 8000
E-mail: certifiedadvisor@penser.se
ABOUT BIOSERGEN
Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to Phase II clinical trials expected to clinically validate BSG005’s potential as a game-changing antifungal treatment. Biosergen’s development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.